Abstract:Purpose/Objective(s) After receiving dose-intensive chemotherapy and gross total resection (GTR), patients with high-risk neuroblastoma (HR-NB) are treated with adjuvant radiation therapy (RT) to the primary site, typically to a dose of approximately 21 Gy. This regimen is associated with excellent local control. However, in these young children, late toxicities to bone, pancreas, and other organs as well as second cancer risk are a major concern. After favorable results in a pilot trial using 18 Gy in 25 patients, we sought to prospectively evaluate local control with a further dose reduction to 15 Gy. Materials/Methods Eligible patients included those with HR-NB (as defined by the Children’s Oncology Group risk stratification schema) who have achieved a GTR of the primary site of disease after induction systemic therapy. Any patients with macroscopic residual disease at the primary site after surgery were excluded. Following surgery, patients were treated with 15 Gy to the primary site in 1.5 Gy fractions twice daily. The primary outcome of the trial was to assess the local failure (LF) rate, as determined by radiographic imaging. Gray’s test was used to compare the incidence of LF across MYCN status. Secondary outcomes included an assessment of event-free survival (EFS), overall survival (OS), and both acute (< 6 months) and late (≥ 6 months) toxicity, as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Results A total of 53 patients were enrolled between 2018-2023 at a single institution. Median follow up from time of RT was 22 months (range = 4-65 months). Median age at the time of RT was 3.5 years (range = 0.8-10.9 years). Primary site was abdominal in 50 patients (94%) and mediastinal in 3 (6%). Forty-four patients (83%) received proton RT. Four patients experienced LF at the primary site of disease (crude risk 7.5%). These failures occurred 1, 3, 8, and 16 months after RT (median 5.5 months). The estimated risk of LF 2 years after RT was 8.4% (95% confidence interval = 2.6%-19%). The risk of LF was not significantly different between patients with MYCN-amplified disease (n = 28) versus those who had non-MYCN-amplified disease (n = 25) (P > 0.9). Six of the 53 patients died (11%); the median OS was not reached. There were 19 instances of any neuroblastoma progression (36%); median EFS was not reached. Of the 53 patients, 16 patients experienced acute toxicity, which included grade 1-2 fatigue, nausea, decreased appetite, diarrhea, and dermatitis. There were no toxicities above grade 2. There were no late toxicities of any grade observed in the cohort of patients, with current dates of follow up. Conclusion For patients with HR-NB who have a GTR of the primary site, reduced-dose RT of 15 Gy is associated with a 2-year LF rate of 8.4%, in line with published data after 21 Gy. The treatment was well-tolerated, with only grade 1-2 acute toxicities and no late toxicities. These data support continued use of 15 Gy for HR-NB. More follow-up is needed to verify a reduction in late effects.

Radiotherapy for Atypical Teratoid/Rhabdoid Tumor (ATRT) on the Pediatric Proton/Photon Consortium Registry (PPCR)

Radiation Therapy Plays an Important Role in the Treatment of Atypical Teratoid/Rhabdoid Tumors: Analysis of the EU-RHAB Cohorts and Their Precursors

Autologous stem cell transplantation in adults with atypical teratoid rhabdoid tumor: a case report and review

Outcomes for children with recurrent/refractory atypical teratoid rhabdoid tumor: A single-institution study with molecular correlation

Proton Radiation Therapy for Pediatric Craniopharyngioma

Primary Atypical Teratoid/Rhabdoid Tumor Of Central Nervous System In Children: A Clinicopathological Analysis And Review Of Literature In China

Long-term outcomes following proton therapy for non-metastatic central nervous system germinoma in children and adolescents

Evolution of Proton Radiation Therapy Brainstem Constraints on the Pediatric Proton/Photon Consortium Registry

Clinical outcomes and late endocrine, neurocognitive, and visual profiles of proton radiation for pediatric low-grade gliomas

Ctni-36. The Feasibility Of Using Bortezomib With Chemotherapy In Atypical Teratoid/Rhabdoid Tumors

Comprehensive radiotherapy for pediatric Ewing Sarcoma: Outcomes of a prospective proton study

Proton Therapy in Non-Rhabdomyosarcoma Soft Tissue Sarcomas of Children and Adolescents

Particle Beam Radiation Therapy for Head and Neck Rhabdomyosarcoma in Adults.

Radt-37. Proton Therapy Reirradiation For Recurrent Malignant Glioma: Prospective Analysis From The Proton Collaborative Group

SDPS-22 THE CLINICAL OUTCOMES OF ATYPICAL TERATOID/RHABDOID TUMOR FROM ONE SINGLE CLINICAL CENTER

Reduced-Dose Radiation Therapy for High-Risk Neuroblastoma: Results from a Prospective Clinical Trial

Atypical teratoid rhabdoid tumor in a lower middle‐income country: Challenges to cure

Analysis of clinical features and prognosis of central nervous system atypical teratoid/rhabdoid tumor

Stereotactic radiotherapy for localized low-grade gliomas in children: final results of a prospective trial

An open invitation to join the Pediatric Proton/Photon Consortium Registry to standardize data collection in pediatric radiation oncology

Disease Control and Toxicity Outcomes after Stereotactic Ablative Radiation Therapy for Recurrent and/or Metastatic Cancers in Young-Adult and Pediatric Patients